NCT00635609

Brief Summary

Randomized, multi-center, open label, active-comparator study to compare the efficacy and tolerability of Doryx Delayed Release Tablets to doxycycline hyclate in patients with moderate to severe acne vulgaris.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
93

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Mar 2008

Shorter than P25 for phase_4

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2008

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

March 7, 2008

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 14, 2008

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2008

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

December 30, 2009

Completed
Last Updated

April 20, 2012

Status Verified

April 1, 2012

Enrollment Period

6 months

First QC Date

March 7, 2008

Results QC Date

September 23, 2009

Last Update Submit

April 18, 2012

Conditions

Outcome Measures

Primary Outcomes (2)

  • Successful Outcome According to Investigator's Global Assessment (IGA)

    The Investigator's Global Assessment (IGA) was performed at baseline and at 12 weeks. The IGA score is based on a 5-point acne severity scale from zero (clear) to 4 (severe). Successful outcome is at least a 2-point reduction in IGA score from baseline to 12 weeks.

    baseline and 12 weeks

  • Change From Baseline in Inflammatory Acne Lesion Count on the Face at 12 Weeks

    Acne lesions fall into 2 groups: inflammatory and non-inflammatory. The number of inflammatory acne lesions on the face was measured at baseline and after 12 weeks. The difference (change) was calculated.

    baseline and 12 weeks

Secondary Outcomes (1)

  • Change From Baseline in Non-inflammatory Acne Lesion Count on the Face at 12 Weeks

    baseline and 12 weeks

Study Arms (2)

Doxycycline hyclate (Doryx)

EXPERIMENTAL
Drug: Doxycycline hyclate (Doryx)

Doxycycline hyclate

ACTIVE COMPARATOR
Drug: Doxycycline hyclate

Interventions

150mg/day, oral, delayed release tablets

Also known as: Doryx
Doxycycline hyclate (Doryx)

100 mg/day, oral, tablets, immediate release

Doxycycline hyclate

Eligibility Criteria

Age12 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Must be 12 years of age or older.
  • Has a diagnosis of facial acne vulgaris with no more than two nodules on the face.

You may not qualify if:

  • Is allergic to tetracycline-class antibiotics or to any ingredient in the study medication.
  • Has a history of pseudomembranous colitis or antibiotic-associated colitis.
  • Has a history of hepatitis or liver damage or renal impairment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Warner Chilcott Investigational Site

Vista, California, 92083, United States

Location

Warner Chilcott Investigational Site

Miami, Florida, 33175, United States

Location

Warner Chilcott Investigational Site

Louisville, Kentucky, 40217, United States

Location

Warner Chilcott Investigational Site

Rochester, New York, 14623, United States

Location

MeSH Terms

Conditions

Acne Vulgaris

Interventions

Doxycycline

Condition Hierarchy (Ancestors)

Acneiform EruptionsSkin DiseasesSkin and Connective Tissue DiseasesSebaceous Gland Diseases

Intervention Hierarchy (Ancestors)

TetracyclinesNaphthacenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolycyclic Compounds

Results Point of Contact

Title
Grexan Wulff, Manager Regulatory Affairs
Organization
Warner Chilcott

Study Officials

  • Angelo Secci, MD

    Warner Chilcott

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
LTE60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 7, 2008

First Posted

March 14, 2008

Study Start

March 1, 2008

Primary Completion

September 1, 2008

Study Completion

September 1, 2008

Last Updated

April 20, 2012

Results First Posted

December 30, 2009

Record last verified: 2012-04

Locations